BRPI0913580A2 - pirrolopiridinas como inibidores de quinase - Google Patents

pirrolopiridinas como inibidores de quinase

Info

Publication number
BRPI0913580A2
BRPI0913580A2 BRPI0913580A BRPI0913580A BRPI0913580A2 BR PI0913580 A2 BRPI0913580 A2 BR PI0913580A2 BR PI0913580 A BRPI0913580 A BR PI0913580A BR PI0913580 A BRPI0913580 A BR PI0913580A BR PI0913580 A2 BRPI0913580 A2 BR PI0913580A2
Authority
BR
Brazil
Prior art keywords
pyrrolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
BRPI0913580A
Other languages
English (en)
Inventor
Bin Wang
Eli M Wallace
Indrani W Gunwardana
James F Blake
Mark Chicarelli
Michael Lyon
Peter J Mohr
Yvan Le Huerou
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913580(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BRPI0913580A2 publication Critical patent/BRPI0913580A2/pt
Publication of BRPI0913580B1 publication Critical patent/BRPI0913580B1/pt
Publication of BRPI0913580B8 publication Critical patent/BRPI0913580B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
BRPI0913580A 2008-05-13 2009-05-13 compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos BRPI0913580B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
US61/052,926 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0913580A2 true BRPI0913580A2 (pt) 2015-10-20
BRPI0913580B1 BRPI0913580B1 (pt) 2020-03-10
BRPI0913580B8 BRPI0913580B8 (pt) 2021-05-25

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913580A BRPI0913580B8 (pt) 2008-05-13 2009-05-13 compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos

Country Status (30)

Country Link
US (6) US8178131B2 (pt)
EP (2) EP2307409B1 (pt)
JP (2) JP5703212B2 (pt)
KR (2) KR101643426B1 (pt)
CN (3) CN104926810B (pt)
AR (1) AR071717A1 (pt)
AU (1) AU2009246402B2 (pt)
BR (1) BRPI0913580B8 (pt)
CA (1) CA2724262C (pt)
CL (1) CL2009001152A1 (pt)
CO (1) CO6321244A2 (pt)
CR (1) CR11803A (pt)
CY (1) CY1116692T1 (pt)
DK (1) DK2307409T3 (pt)
ES (1) ES2552643T3 (pt)
HK (2) HK1152035A1 (pt)
HR (1) HRP20151018T1 (pt)
HU (1) HUE026160T2 (pt)
IL (1) IL209258A (pt)
MX (1) MX2010012449A (pt)
NZ (1) NZ589318A (pt)
PH (1) PH12013501779B1 (pt)
PL (1) PL2307409T3 (pt)
PT (1) PT2307409E (pt)
RS (1) RS54358B1 (pt)
RU (1) RU2517194C2 (pt)
SI (1) SI2307409T1 (pt)
TW (2) TWI554512B (pt)
UA (1) UA111933C2 (pt)
WO (1) WO2009140320A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2242755B1 (en) 2008-01-08 2012-09-12 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
AU2010233122B2 (en) * 2009-04-11 2015-09-17 Array Biopharma Inc. Checkpoint kinase 1 inhibitors for potentiating DNA damaging agents
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
JP6091422B2 (ja) * 2010-11-16 2017-03-08 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
ES2563152T3 (es) 2011-02-25 2016-03-11 Array Biopharma Inc. Compuestos de triazolopiridina como inhibidores de quinasa PIM
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
SG11201406818VA (en) 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
MX369174B (es) * 2013-08-22 2019-10-30 Genentech Inc Proceso para la preparación de un compuesto.
WO2015048318A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
AR101106A1 (es) 2014-07-02 2016-11-23 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko) 2015-06-30 2017-01-05 서울바이오시스 주식회사 Uv led가 적용된 포충기
LT3371165T (lt) * 2015-11-04 2022-05-10 Merck Patent Gmbh Btk inhibitorius, naudojamas vėžiui gydyti
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
KR102436430B1 (ko) 2016-06-10 2022-08-24 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
MA53095A (fr) 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173459A1 (en) 1993-10-14 1995-04-20 Daniel T. Chu Quinolizinone type compounds
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CA2494785A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
MXPA05009885A (es) 2003-03-14 2005-12-05 Astrazeneca Ab Nuevas triazolonas fusionadas y los usos de las mismas.
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
CA2561724A1 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
AU2005244745B2 (en) * 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
RU2007140734A (ru) 2005-04-06 2009-05-20 Астразенека Аб (Se) Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
RU2376300C1 (ru) * 2005-08-30 2009-12-20 Асахи Касеи Фарма Корпорэйшн Сульфонамидное соединение
EP1942900B1 (en) 2005-10-06 2015-06-03 Merck Sharp & Dohme Corp. Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
EP2217611B1 (en) 2007-11-07 2013-07-31 Merck Sharp & Dohme Corp. Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2242755B1 (en) * 2008-01-08 2012-09-12 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP6091422B2 (ja) 2010-11-16 2017-03-08 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ

Also Published As

Publication number Publication date
CR11803A (es) 2011-02-11
CA2724262C (en) 2017-08-15
US8545897B2 (en) 2013-10-01
KR101643426B1 (ko) 2016-07-27
CN104926810A (zh) 2015-09-23
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
JP2011520896A (ja) 2011-07-21
KR20110008102A (ko) 2011-01-25
RS54358B1 (en) 2016-04-28
JP5703212B2 (ja) 2015-04-15
CN102089307A (zh) 2011-06-08
CN109942575A (zh) 2019-06-28
AU2009246402B2 (en) 2013-05-23
AR071717A1 (es) 2010-07-07
JP2015098482A (ja) 2015-05-28
US8758830B2 (en) 2014-06-24
US20140100369A1 (en) 2014-04-10
TWI554512B (zh) 2016-10-21
PT2307409E (pt) 2015-11-04
KR101657856B1 (ko) 2016-09-19
PH12013501779A1 (en) 2014-08-27
US9969727B2 (en) 2018-05-15
CY1116692T1 (el) 2017-03-15
US8178131B2 (en) 2012-05-15
US9365568B2 (en) 2016-06-14
BRPI0913580B1 (pt) 2020-03-10
CN104926810B (zh) 2019-02-19
TW201002707A (en) 2010-01-16
PL2307409T3 (pl) 2016-01-29
US20160368916A1 (en) 2016-12-22
CO6321244A2 (es) 2011-09-20
HK1219950A1 (zh) 2017-04-21
US20140243520A1 (en) 2014-08-28
IL209258A (en) 2017-01-31
HK1152035A1 (en) 2012-02-17
SI2307409T1 (sl) 2015-11-30
RU2517194C2 (ru) 2014-05-27
UA111933C2 (uk) 2016-07-11
AU2009246402A1 (en) 2009-11-19
US20130045286A1 (en) 2013-02-21
MX2010012449A (es) 2011-05-25
CA2724262A1 (en) 2009-11-19
US8981085B2 (en) 2015-03-17
ES2552643T3 (es) 2015-12-01
CL2009001152A1 (es) 2009-10-16
US20150322061A1 (en) 2015-11-12
BRPI0913580B8 (pt) 2021-05-25
PH12013501779B1 (en) 2014-08-27
WO2009140320A1 (en) 2009-11-19
RU2010150786A (ru) 2012-06-20
IL209258A0 (en) 2011-01-31
KR20140093266A (ko) 2014-07-25
HRP20151018T1 (hr) 2015-10-23
CN102089307B (zh) 2015-07-01
EP2990407A1 (en) 2016-03-02
TWI458727B (zh) 2014-11-01
EP2990407B1 (en) 2019-10-16
EP2307409B1 (en) 2015-08-12
NZ589318A (en) 2011-06-30
HUE026160T2 (en) 2016-05-30
TW201529573A (zh) 2015-08-01
US20110070317A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
CY2019027I2 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0908494A2 (pt) Inibidores de pirrolopirazina quinase
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0811434A2 (pt) imidazopiridazinas como inibidores de pi3k lipídeo cinase.
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0908849A2 (pt) Composto e composições como c-kit e inibidores de pdgfr quinase
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
DK2376490T3 (da) Imidazopyridinforbindelser
BRPI0811516A2 (pt) Compostos e composições como inibidores de c-kit e pdgfr cinase
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
DK2414362T3 (da) Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
BRPI0921156A2 (pt) inibidores de pi3k/mtor quinase
BRPI1005327A2 (pt) derivados de triazolopiridina como inibidores de p38 map quinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.